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Acute bacterial meningitis (ABM) is an acute inflammation of leptomeninges caused by
bacteria, and has a case fatality rate of 10–30%. Prevention strategies, such as vaccination
and prophylactic antibiotics, can prevent ABM and have substantial public health impact
by reducing the disease burden associated with it. The aim of this paper is to summarize
the main findings from Cochrane systematic reviews that have considered the evidence for
measures to prevent ABM. We assessed the evidence available in the Cochrane Library. We
found five Cochrane reviews focused on the prevention of ABM; three with use of
vaccination and two with prophylactic antibiotics. Polysaccharide serogroup A vaccine is
strongly protective for the first year, against serogroup A meningococcal meningitis in
adults and children over 5 years of age. Meningococcal serogroup C conjugate (MCC)
vaccine is safe and effective in infants. Haemophilus influenzae type b (Hib) vaccine is safe
and effective against Hib-invasive disease at all ages. Ceftriaxone, rifampicin and
ciprofloxacin are the most effective prophylactic antibiotics against Neisseria meningiti-
dis. There is sufficient evidence to use polysaccharide serogroup A vaccine to prevent
serogroup A meningococcal meningitis, MCC conjugate vaccines to prevent meningococcal
C meningitis and Hib conjugate vaccine to prevent Hib infections. More studies are needed
to evaluate the effects of Hib conjugate vaccine on mortality. Further, studies are required
to compare the relative effectiveness of ceftriaxone, ciprofloxacin and rifampicin in
chemoprophylaxis against meningococcal infection.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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K. Prasad, N. Karlupia2038Background More than one reviewer independently assessed eligibilityAcute bacterial meningitis (ABM) is defined as an acute
inflammation of leptomeniges (pia-arachnoid) caused by bac-
teria. ABM is a major cause of death and disability, especially in
developing countries. Despite advances in neuroimaging and
critical care, the case fatality rate of ABM remains around
10–30%. An additional 5–40% of cases have only partial recovery
with late sequelae.1 Effective preventive and treatment
strategies are required to reduce mortality and morbidity.
In this paper, we review the available evidence on
measures for preventing ABM. We will restrict ourselves to
interventions that have been the subject of Cochrane
systematic reviews, as these reviews make systematic
attempts to synthesize high-quality evidence from rando-
mized-controlled trials (RCTs), and may be considered the
highest level in the hierarchy of evidence.
Methods
In October 2006, we searched the Cochrane Library (Issue 3,
2006) for relevant reviews using ‘meningitis’ as a search
term. The titles of all the search results were examined to
select reviews on prevention of ABM. The full text of each of
the selected reviews were printed out and studied.
Results
The initial search yielded 127 hits. After examining the
titles, we selected five reviews as relevant to the topic.
Reviews were excluded if they addressed other types of
meningitis (e.g. tubercular or cryptococcal), or if they did
not address interventions for ABM but were found by the
search strategy because the word ‘meningitis’ was men-
tioned for other reasons.
Although some reviews included both RCTs and non-
randomized studies, we have considered mainly the results
of only the RCTs. Several Cochrane reviews have addressed
the efficacy of vaccines to prevent pneumococcal infection,
including invasive infection. However, none of these reviews
contain information that specifies the effect of vaccines on
the incidence of pneumococcal meningitis. This applies to
reviews on vaccines to prevent pneumococcal infection.
Protocols were also excluded. A brief summary of all the
reviews is presented in Table 1. For each selected review,
we provide below the details of methods and results.
Methods common to all reviews
All the included Cochrane reviews were selected after
searching the literature in various databases, mainly Med-
line, Embase and the Cochrane Central Register of Con-
trolled Trials. In addition, most reviewers used other
strategies to find relevant studies. The strategies included
searching of specialized databases within the Cochrane
Collaboration, such as the Cochrane Airways Group Trials
Register or Cochrane Infectious Diseases Group Trial Regis-
ter, checking references of relevant articles, writing to
manufacturers of vaccines and drugs, and writing to authors
for additional studies.of the studies for their review, their methodological quality
and extracted the data. All reviews used the Cochrane
Collaboration software Revman to synthesize their results.
Cochrane review on polysaccharide vaccines
for serogroup A meningococcal meningitis
Serogroups A–C of Neisseria meningitidis account for most
cases of meningococcal meningitis throughout the world.
Although serogroup A dominates across Africa, serogroups B
and C are responsible for most cases in industrialized
countries.7,8 Large epidemics of serogroup A occur in the
sub-Saharan ‘meningitis belt’ that extends from Ethiopia in
the east to Senegal in the west.9,10
The main objectives of this review were to determine the
effect of polysaccharide serogroup A vaccine for preventing
serogroup A meningococcal meningitis, to assess age-
specific effects of this vaccine, the effects of booster doses
in children under 5 years of age and the duration of
protection in children and adults.
The last search of the literature for this Cochrane review
was carried out in November 2004. The authors included
eight RCTs; they also included one case–control study and
one historical cohort study, but both had high risk of bias and
low statistical power. The unit of allocation was individual
participant in three trials, community clusters in four, school
class in one, household in one and village in one.
The eight RCTs revealed consistent results. The remark-
able consistency across the trials conducted in widely
diverse settings, with epidemic and endemic disease, in
developed and developing countries provided support for
generalizability of research findings.
Overall, the vaccine efficacy in the eight trials combined
was 95% (95% confidence interval [CI] 87–99%) in the first
year after vaccination, in participants aged over 5 years.
There was insufficient evidence to determine the duration
of protection beyond 1 year after vaccinating adults and
children over 5 years of age. In one study from Finland, the
vaccine was protective in children aged 3 months to 5 years.
However, the vaccine efficacy within the age sub-categories
of these children could not be determined because of the
small number of children in the study. For the same reason,
the effect of single versus two doses of vaccine in children
aged 3–17 months of age could not be determined.
The authors of this review concluded that the polysacchar-
ide serogroup A vaccine is strongly protective against
serogroup A meningococcal meningitis in adults and children
over 5 years of age for the first year after vaccination. The
vaccine is probably also protective in children aged 3 months
to 5 years, but only a few trials have addressed this issue.
There is insufficient evidence to determine protection beyond
1 year after vaccination and to support or refute the use of
booster doses in children younger than 2 years of age.
Cochrane review on conjugate vaccines for
preventing meningococcal C meningitis and
septicaemia
Serogroup C meningococcal meningitis has been recorded
in epidemics in Africa, the Middle East and the Indian
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Table 1 Summary of Cochrane reviews.
Topic Most recent
search
Number of
studies
included
Conclusions
Polysaccharide vaccines for
preventing serogroup A
meningococcal meningitis2
2004 8 RCT, 2
non-RCTs
The polysaccharide serogroup A vaccine is strongly
protective against serogroup meningococcal meningitis in
children over 5 years of age and adults for the first year
after vaccination. Insufficient evidence to determine
efficacy and duration of protection across age strata in
children younger than 5 years of age. Insufficient
evidence to determine value of booster dose in children
younger than 2 years of age.
Conjugate vaccines for
preventing meningococcal C
meningitis and septicaemia3
2005 14 RCTs, 8
CCTs
MCC vaccine is clinically effective. MCC vaccine is more
immunogenic than MPLS vaccine in all age groups. MCC
vaccine seems to be safe and able to induce
immunological memory in all age groups. MCC is
preferred as a booster dose for those previously
vaccinated with MPLS.
Conjugate vaccines for
preventing Haemophilus
influenzae type b infections4
2003 5 RCTs Hib vaccine is safe and effective against Hib disease, size
of effect is uncertain. In resource-poor settings, use of
vaccine will depend on cost, local burden of Hib disease
and competing priorities. Effects of Hib conjugate
vaccine on either Hib-specific or on all-cause mortality
were uncertain.
Antibiotics for preventing
meningococcal infections5
2004 24 RCTs Despite rifampicin’s eradication, efficacy of its use in an
outbreak setting might lead to circulation of isolates
resistant to rifampicin, so use of ciprofloxacin and
ceftriaxone should be considered. Prophylactic treatment
has proven to reduce risk of disease among household
contacts, thus placebo-controlled trials are unethical.
Antibiotic prophylaxis for
preventing meningitis in
patients with basilar skull
fractures6
2005 5 RCTs, 17
non-RCTs
No effect of prophylactic antibiotics on the prevention of
meningitis in patients with BSF, regardless of CSF leakage.
CCT, controlled clinical trial; CSF, cerebrospinal fluid; Hib, Haemophilus influenzae type B; MCC, meningococcal serogroup; MPLS,
meningococcal polysaccharide.
Prevention of bacterial meningitis 2039sub-continent. It has been responsible for 25–68% of all
meningococcal cases in Europe, America and Australia.11
Age-specific incidence peaks between 6 and 12 months after
birth in developed countries.12 Vaccines against serogroup C
meningococcal disease are available in combination with
serogroups A, W-135 and Y, based on their capsular
polysaccharides. However, the polysaccharide vaccines have
several limitations. The serogroup C component is not
immunogenic in infants under 2 years of age,13–16 thus
failing to protect those at greatest risk of disease. In older
children, there is protection but it is short lived. These
deficiencies of the polysaccharide vaccines have been
overcome with the development of conjugate vaccines, in
which the capsular polysaccharides are covalently linked to
carrier proteins. Tetanus toxoid, diphtheria toxoid or
CRM197, a non-toxic mutant of diphtheria toxin, have been
used as carrier proteins. Conjugation converts the thymus-
independent polysaccharide into a thymus-dependent im-
munogen. This results in engagement of T cells in the
induction of antibodies in infants and memory responses.
The main objective of this review was to assess theimmunogenecity, safety and efficacy of the conjugate
vaccines in prevention of serogroup C meningococcal
meningitis.
The last search of the literature for this review was
carried out in September 2005. The authors set out to
identify RCTs and controlled clinical trials (CCTs). However,
RCTs evaluated only immunogenicity and safety. In the
absence of any RCT with clinical end points, the authors
decided to include population-based observational studies
to determine clinical efficacy of the vaccines. All age groups
from infants to adults were included.
Twenty-four studies involving 28 reports were included.
Eighteen were RCTs and four observational studies. Overall,
the quality of RCTs was good. The conjugated vaccine
meningococcal serogroup C conjugate (MCC) was directed
against serogroup C (11 studies), AC (5 studies) or ACYW135
(1 study). One study evaluated a combination 9–valent
pneumococcal MCC. The oligosaccharide C was conjugated
to CRM197 (cross-reacting material) non-toxic mutant of
diphtheria toxin in all except three trials. In these three
trials, the oligosaccharide was conjugated to tetanus toxoid.
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genic in infants after two and three doses, in toddlers after
one and two doses and after a single dose in older age
groups.
The authors of the review concluded that, after one dose,
the MCC vaccine was shown to be safe in infants. The
adverse events reported (more frequently in infants) were
as follows: fever (1–5%), irritability (38–67%), crying more
than expected (1–13%), redness (6–97%), tenderness
(11–13%) and swelling (6–42%) at the site of vaccination.
Observational studies showed that there was a rapid
decline in group C meningococcal disease in England,
Quebec and Spain, following the introduction of MCC
vaccination into the routine infant schedule, together with
an extensive catch-up vaccination campaign of young
children and teenagers. The studies screened the population
for meningococcal C disease and evaluated the effective-
ness of the vaccine using the screening method explained
below.
The screening method of analysis is based on a compar-
ison of the proportion vaccinated among the cases and the
population.17,18 On the basis of this method of analysis,
after 1 year, MCC vaccine effectiveness was established to
be 83–99.5% in those vaccinated after 7 months of age. In
general, conjugate vaccines generated higher titers than
polysaccharide vaccines. Immune responses seem to be
better when the vaccine is given later in the first year of
life. Most studies used three doses in infants but two doses
may be adequate, particularly with the tetanus toxoid
conjugate. In children aged between 12 and 18 months of
age, two doses of MCC generates high antibody titers and
most have protective titers after single dose, particularly
with the tetanus toxoid conjugate. One dose seems to be
sufficient after 2 years of age. According to the observa-
tional studies, there can be a decline in protection after
primary vaccination, and this may be more marked when
children are vaccinated in the first year of life. The MCC
vaccine is found to be more immunogenic than meningo-
coccal polysaccharide (MPLS) in all age groups, and is
preferred as a booster dose for those previously vaccinated
with MPLS.
The authors supported the inclusion of MCC vaccine into
national immunization programs in areas where meningo-
coccal C disease is a substantial public health problem.
Cochrane review on conjugate vaccines for
preventing Haemophilus influenzae type b
infections
H. influenzae type b (Hib) is one of the ‘big three’ causes of
ABM and pneumonia in children under 5 years of age. It is
estimated to cause at least 3 million cases of serious disease
and hundreds of thousands of deaths annually, worldwide
(WHO, 1998). The main objective of this review was to
determine the effects of conjugate Hib vaccine in prevent-
ing Hib disease or death in children under 5 years and to
determine whether Hib conjugate vaccine causes any
serious adverse effects. The last search of the literature
for the Cochrane review was conducted in April 2003. The
authors included four RCTs and one quasi-randomized trial.
The overall quality of the randomized trials was good. Thestudy population consisted of children younger than 5 years
of age, irrespective of HIV status. Outcomes planned to be
studied were all-invasive Hib diseases, all-cause mortality,
Hib-specific mortality, cause-specific mortality from menin-
gitis and pneumonia, and any adverse events due to Hib
vaccination.
The use of vaccine was associated with risk reduction of
80% (RR 0.20, 95% CI 0.07–0.54). The size of effect did not
seem to differ with different vaccine types, number of
vaccine doses or age at first vaccination.
Hib-related mortality data were available from two trials
included in the meta-analysis, and showed a non-significant
trend towards benefit, with an estimate of about 70%
reduction (relative risk: 0.29), but the wide confidence
interval (0.07–1.20) did not exclude a harmful effect, and
also reflected the paucity of information available. There
were no reports of any serious adverse effects from any of
these trials involving 257,000 infants.
The authors of the review concluded that Hib vaccine is
safe and effective against Hib-invasive disease; however,
the size of effect was uncertain. Effects of Hib conjugate
vaccine on either Hib-specific or on all-cause mortality were
uncertain. It was concluded that, in resource-poor settings,
use of vaccine will depend on its cost, local burden of Hib
disease and competing priorities.Cochrane review on antibiotics for preventing
meningococcal infections
Meningococcal meningitis is spread by person-to-person
contact through respiratory droplets. The causative organ-
ism, N. meningitis, first colonizes the nasopharynx of
contacts, turning them into carriers, who spread the disease
to others, but also some of them develop meningitis or
septicaemia. Individuals in close contact with people with
meningococcal disease are at increased risk for developing
disease (WHO, 2003a).19 Antibiotic prophylaxis is considered
for those in close contact with cases (e.g., people living in
the same household during the first 7 days after a case) and
in populations with known high carriage rates.
The authors set out to summarize the evidence of
effectiveness of different antibiotic prophylactic treatments
in (1) preventing secondary cases of meningococcal disease
after contact with a person with meningococcal disease,
both within and outside the household; (2) preventing cases
of meningococcal disease in populations with a high rate of
N. meningitidis carriers; and (3) eradicating N. meningitidis
from the pharynx in healthy carriers of N. meningitidis.
Authors included randomized or quasi-randomized clinical
trials in N. meningitdis carriers and healthy individuals
exposed to people with meningococcal disease or belonging
to a population with a high rate of N. meningitidis carriers,
regardless of their carrier status. Outcomes studied were
mortality and morbidity due to meningococcal disease and
failure to eradicate N. meningitidis from the nasopharynx.
The last search of the literature for the Cochrane review
was conducted in September 2004. The authors included 23
randomized and two quasi-randomized trials. Study popula-
tion included household contacts (six trials), army recruits
(seven trials), students (four trials), volunteers (three),
children (one) and unspecified (one). There were no deaths
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were recorded in one study). Two had one case each of
meningococcal disease but one occurred before prophylaxis
had begun and the second occurred 12 weeks after
treatment with rifampicin. Three other trials did not have
any meningococcal disease. Clinical effectiveness (preven-
tion of disease) of chemoprophylaxis, therefore, could not
be assessed. All trials reported failure to eradicate N.
meningitidis from the nasopharynx as the main outcome.
At 1 week after treatment, effective antibiotics (com-
pared with placebo) were ciprofloxacin (relative risk [RR]
0.04; 95% CI 0.01–0.12), rifampicin (RR 0.17; 95% CI
0.12–0.24), minocycline (RR 0.30; 95% CI 0.19–0.45) and
ampicillin (RR 0.41; 95% CI 0.25–0.66). Between 1 and 2
weeks’ follow-up, only rifampicin (RR 0.20; 95% CI
0.14–0.29) and ciprofloxacin (RR 0.03; 95% CI 0.00–0.42)
proved effective.
Minocycline and penicillin were found effective, although
95% CIs were wide. Ceftriaxone was more effective than
rifampicin (only one study RR 5–93; 95% CI 1.22–28.68).
Rifampicin continued to be effective compared with placebo
up to 4 weeks after treatment, but resistant isolates were
seen after prophylaxis.
Authors of the review concluded that the most effective
antibiotics to achieve eradication of N. meningitidis from
nasopharynx are ceftriaxone, rifampicin and ciprofloxacin.
Rifampicin is usually the drug of choice, but in view of
emergence of resistant isolates, they recommend caution in
its use during outbreaks. They recommend considering use
of ciprofloxacin and ceftriaxone as there have been no
development of resistance to them. Ciprofloxacin can be
given in a single dose thus ensuring compliance and minimal
side-effects, but is contraindicated in pregnancy and
children. Ceftriaxone is safe for children and pregnant
woman. It is administered in a single intramuscular dose to
ensure adherence to prophylaxis, even though it causes
more frequent but mild adverse effects compared with
rifampicin.
Cochrane review of antibiotic prophylaxis for
preventing meningitis with basilar skull
fractures
Basilar skull fractures (BSF) may place the central nervous
system in direct contact with bacteria from paranasal
sinuses, nasopharynx or middle ear. Association of cere-
brospinal fluid (CSF) leak with the fractures indicates torn
duramater and increases risk of developing meningitis.20
The main objective of this review was to determine whether
prophylactic antibiotics administered as soon as a diagnosis
of BSF is made (with or without CSF leakage), decreases the
incidence of meningitis compared with no antibiotic.
The last search of the literature for this Cochrane review
was carried out in September 2005. The authors included
both randomized and non-randomized controlled trials,
comparing any antibiotic with placebo or no intervention.
Patients of all ages, with or without CSF leakage, were
included. Frequency of meningitis, mortality and non-CNS
infection were the outcome measures.
Four RCTs with 208 patients were included in the meta-
analysis in general. The quality of the trials was poor. Nostatistically significant differences were found in the
frequency of meningitis (Peto odds ratio [OR] 0.68; 95% CI
or 0.28–1.65), mortality (Peto OR 1.76; 95% CI 0.41–7.60) or
non-CNS infection (Peto OR 0.62; 95% CI 0.16–2.41). No
statistically significant differences were found in the
subgroups of patients with or without CSF leakage (Peto
OR 0.37; 95% CI 0.06–2.24 vs. Peto OR 0.77; 95% CI
0.25–2.38, respectively). Meta-analysis of 17 non-RCTs with
2168 patients (treatment group 1141; control group 1027)
yielded similar results (OR 1.13; 95% CI 0.67–1.88). However,
all the above 95% CIs are very wide and do not exclude a
clinically important difference.
The authors concluded that there is insufficient evidence
to support or refute the use of antibiotics in the prophylaxis
of meningitis in patients with BSF. Large, methodologically
sound studies are needed.Discussion
ABM is associated with high mortality and morbidity.21
Prevention strategies can minimize mortality and morbidity.
We found five Cochrane reviews that focused on prevention
of ABM. The preventive strategies reviewed were vaccines
(three reviews) and antibiotics (two reviews).
In reviews on prevention, the most recent search was
carried out between 2004 and 2006. They show that the
available vaccines are immunogenic and safe. There is
evidence to show that polysaccharide serogroup A vaccine
protects against serogroup A meningococcal disease. Con-
jugate vaccines against subgroup C meningococcal disease
generate higher levels of titers of protective antibodies than
the polysaccharide vaccines. Chemoprophylaxis is effective
in eradicating carrier sate. These reviews raise a very
important question. When dealing with a life-threatening
disease such as meningitis, should or should we not accept
evidence on surrogate outcomes (such as antibody titers or
carrier eradication rate) as sufficient to make recommenda-
tions. This issue has been discussed in detail by Bucher et
al.22 If surrogate outcomes are strongly correlated with the
final outcomes, and if multiple studies consistently show
benefit in term of the surrogate outcomes, then it may be
acceptable to recommend the intervention. Therefore, it
seems that further clinical trials to demonstrate clinical
effectiveness to conjugate meningococcal subgroup C
vaccines may be unnecessary and probably unethical.
However, lack of lasting immunity of polysaccharide
meningococcal A vaccine and its uncertain efficacy in infants
calls for urgent development and clinical testing of
conjugate vaccines that are undergoing immunogenicity
trials.23 The availability of effective vaccine may not be
enough to control (or hopefully eradicate in due course) the
meningococcal disease. What is required is a policy and
effective implementation of the policy by vaccinating
people on a scale that will prevent the disease from
occurring.
In this context, a noteworthy point is that childhood Hib
meningitis has nearly been eliminated in the Western world
after routine vaccination with conjugate Hib vaccines.24
Some countries may consider introducing the vaccines
to prevent meningococcal disease in their national
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and cost-effectiveness.
Others may consider selective immunization to high-side
groups. In high-risk people, antibiotic prophylaxis is also an
effective strategy to prevent or eradicate carriage. How-
ever, most antibiotic studies provided evidence of efficacy
during the first 1 or 2 weeks. Only rifampicin has been
studied up to 4 weeks.24 Role of antibiotics in preventing
meningitis after BSF remains unclear.
The vaccine reviews need to be updated as and when new
trials are published, although it is probably unethical to
conduct placebo-controlled trials of a new vaccine. Cer-
tainly, attempts to develop conjugate meningococcal
serogroup A vaccines are on the horizon.25,26 No Cochrane
review on meningococcal serogroup B vaccine has been
conducted. Such a review is important because serogroup B
meningococcus accounts for 68% of cases reported in Europe
from 1993 to 1996, and has also caused outbreaks
in developed countries with attack rates of 5–50 cases
per 100,000 persons.27 Meningitis in countries such as New
Zealand has increased because of meningococcal sero-
group B.28
The Cochrane reviews presented here provide methodo-
logically sound evidence because all have focused on RCTs.
However, some3 have included observational studies. The
extent of bias in these studies is unclear, but similarity of
the effect estimates provides assurance that the bias is
unlikely to be higher.Conclusions
Cochrane systematic reviews support the use of polysac-
charide serogroup A vaccine to prevent serogroup A
meningococcal meningitis, MCC vaccines to prevent menin-
gococcal C meningitis and Hib conjugate vaccine to prevent
Hib infections. There is a lack of evidence for or against the
use of prophylactic antibiotics to prevent meningitis in
patients with BSF. More studies are required to compare the
relative effectiveness of ceftriaxone, ciprofloxacin and
rifampicin in chemoprophylaxis against meningococcal
infection.Practice points Polysaccharide serogroup A vaccine is effective in
preventing serogroup A meningococcal meningitis in
adults as well as children beyond 3 months of age. MCC vaccine is effective in preventing meningococcal C
meningitis and may be included in the National Immuno-
logy Program in areas where meningococcal disease is a
substantial public health problem. Use of Hib conjugate vaccine is safe and effective for Hib-
invasive disease. Ciprofloxacin may be the antibiotic of choice for
chemoprophylaxis against meningococcal meningitis ex-
cept in children and pregnant women for whom ceftriax-
one may be the drug of choice. Insufficient evidence exists for or against the use of
antibiotics to prevent meningitis in patients with BSF.Research directions Correlation between antibody levels induced by poly-
saccharide serogroup A vaccine and clinical protection
needs to be studied through systematic reviews and
observational studies. More studies of MCC vaccines are required to address the
immunogenicity of MCC at different time schedules and
to analyze the influence of other vaccines given
concomitantly. There is a need for a Cochrane review
on meningococcal serogroup B vaccine. Vaccine field trials are required to evaluate the effects of
Hib conjugate vaccine on either Hib-specific or on all-
cause mortality. Trials comparing the relative effectiveness of ceftriax-
one, ciprofloxacin, rifampicin and oral third-generation
cephalosporins for eradication of N. meningitidis are
needed. Large methodologically sound studies are needed to
evaluate the effectiveness of prophylactic antibiotics in
case of patients with BSFs.
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